Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | DRD3 | P35462 | 2/20 | 0.43 |
| ▸ | HTR1D | P28221 | 1/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.40 |
| ▸ | NQO2 | P16083 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 6/20 | 0.39 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.39 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | DRD5 | P21918 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2810662 | 0.93 | DRD2 (0.47) | DRD2DRD3HTR1DMTNR1AMTNR1B | |
| SCHEMBL4522568 | 0.88 | DRD2 (0.42) | DRD2DRD3HTR1DMTNR1AMTNR1B | |
| SCHEMBL4522562 | 0.88 | DRD2 (0.42) | DRD2DRD3HTR1DMTNR1AMTNR1B | |
| SCHEMBL14711226 | 0.83 | TAS1R3 (0.51) | MTNR1AMTNR1BNQO2KDM4CTAS1R3 | |
| SCHEMBL30940169 | 0.83 | TAS1R3 (0.51) | MTNR1AMTNR1BNQO2KDM4CTAS1R3 | |
| SCHEMBL25214790 | 0.80 | DRD2 (0.46) | DRD2DRD3HTR1DDRD1DRD4 | |
| SCHEMBL3533743 | 0.80 | DRD2 (0.43) | DRD2DRD3HTR1DKDM4CDRD1 | |
| SCHEMBL3533741 | 0.80 | DRD2 (0.43) | DRD2DRD3HTR1DKDM4CDRD1 | |
| SCHEMBL2629485 | 0.77 | DRD2 (0.43) | DRD2DRD3HTR1DDRD1DRD4 | |
| SCHEMBL3539919 | 0.77 | DRD2 (0.43) | DRD2DRD3HTR1DDRD1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8975235-B2 | Lysophosphatidic acid receptor antagonists | INTERMUNE, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-20130072449-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| WO-2013025733-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. (US) | 2013-02-21 | — | — | WO | disclosed |
| US-20100249179-A1 | Farnesoid X Receptor Agonists | SMITHKLINE BEECHAM CORPORATION (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249179-A1 | Farnesoid X Receptor Agonists | SMITHKLINE BEECHAM CORPORATION (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249179-A1 | Farnesoid X Receptor Agonists | SMITHKLINE BEECHAM CORPORATION (US) | 2010-09-30 | — | — | US | disclosed |
| EP-2170072-A1 | FARNESOID X RECEPTOR AGONISTS | GlaxoSmithKline LLC (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2008157270-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008157270-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072449-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR5 | DRD2 2643/4885DRD3 3112/4885HTR1D 1115/4885 |
| US-20100249179-A1 | Farnesoid X Receptor Agonists | NR1H4, NR1H3, NR1H2 | DRD2 4361/4885DRD3 3672/4885HTR1D 2354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.